Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Glycemic effect of pancreatic preproglucagon in mouse sleeve gastrectomy
Ki-Suk Kim, Chelsea R. Hutch, Landon Wood, Irwin J. Magrisso, Randy J. Seeley, Darleen A. Sandoval
Ki-Suk Kim, Chelsea R. Hutch, Landon Wood, Irwin J. Magrisso, Randy J. Seeley, Darleen A. Sandoval
View: Text | PDF
Research Article Endocrinology Metabolism

Glycemic effect of pancreatic preproglucagon in mouse sleeve gastrectomy

  • Text
  • PDF
Abstract

Intestinally derived glucagon-like peptide-1 (GLP-1), encoded by the preproglucagon (Gcg) gene, is believed to function as an incretin. However, our previous work questioned this dogma and demonstrated that pancreatic peptides rather than intestinal Gcg peptides, including GLP-1, are a primary regulator of glucose homeostasis in normal mice. The objective of these experiments was to determine whether changes in nutrition or alteration of gut hormone secretion by bariatric surgery would result in a larger role for intestinal GLP-1 in the regulation of insulin secretion and glucose homeostasis. Multiple transgenic models, including mouse models with intestine- or pancreas tissue–specific Gcg expression and a whole-body Gcg-null mouse model, were generated to study the role of organ-specific GLP-1 production on glucose homeostasis under dietary-induced obesity and after weight loss from bariatric surgery (vertical sleeve gastrectomy; VSG). Our findings indicated that the intestine is a major source of circulating GLP-1 after various nutrient and surgical stimuli. However, even with the 4-fold increase in intestinally derived GLP-1 with VSG, it is pancreatic peptides, not intestinal Gcg peptides, that are necessary for surgery-induced improvements in glucose homeostasis.

Authors

Ki-Suk Kim, Chelsea R. Hutch, Landon Wood, Irwin J. Magrisso, Randy J. Seeley, Darleen A. Sandoval

×

Figure 1

Tamoxifen-inducible intestinal Gcg reactivation in mice.

Options: View larger image (or click on image) Download as PowerPoint
Tamoxifen-inducible intestinal Gcg reactivation in mice.
(A) A brief sch...
(A) A brief schematic of the generation of the GcgRAΔVilCreERT2 mice. Mating of tamoxifen-inducible Villin-Cre mouse (VilCreERT2) with Gcg-null mouse (GcgRAΔNull) generates GcgRAΔVilCreERT2 offspring with intestinal Gcg reactivation. (B) Gcg gene expression from the hindbrain, pancreas, duodenum, jejunum, and ileum of GcgRAΔVilCreERT2 mice was not detectable in the hindbrain and pancreas but was at similar levels in all 3 sections of the small intestine compared with VilCreERT2 littermate controls. (C) Glucose response to an oral glucose load and an i.p. injection of saline (Sal) or exendin 9-39 (Ex9); 3-way ANOVA with Tukey post hoc; P < 0.001 for Cre-Sal versus Cre-Ex9, but not significant for RA-Sal versus RA-Ex9 (genotype × drug); ***P < 0.001 for Cre versus RA in both drug-treated groups (time × genotype). (D) Glucose incremental area under the curve (iAUC) during the oral glucose tolerance test (OGTT); 2-way ANOVA with Tukey post hoc; ***P < 0.001 (genotype × drug). All data were obtained from cohort 1, each animal was only studied once per condition, and data are represented as Mean ± SEM. VilCreERT2 (n = 17); GcgRAΔVilCreERT2 (n = 10).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts